This CME/CE program will highlight recent advances in the treatment and management of patients with relapsed/refractory multiple myeloma (RRMM). The expert faculty, led by C. Ola Landgren, MD, will first discuss best practices for integrating BCMA-targeted therapy into treatment plans for patients with RRMM. Following, emerging therapies in relapsed and remitting multiple myeloma will be reviewed, analyzing both current options and future directions. The faculty will conclude with an overview of symptom management, supportive care, and quality of life in patients with multiple myeloma receiving newer therapies. Upon completion of this activity, learners will be better equipped to provide effective, comprehensive care for patients with RRMM.
Hematologist-oncologists, oncologic nurses, advanced practice providers, and other healthcare professionals involved in the care of people with multiple myeloma
- Understand the science and clinical applications of predictive biomarkers and anti BCMA therapeutics to manage patients with multiple myeloma
- Review the clinical trial data including presentations from ASH 2021 for the optimal treatment of patients with relapsed/refractory multiple myeloma
- Utilize the healthcare team and patient education to optimize the delivery of care to multiple myeloma patients
Ola Landgren, MD, PhD (Course Chair)
Chief, Myeloma Program
Leader, Experimental Therapeutics Program
Co-leader, Tumor Biology Program
University of Miami, Sylvester Comprehensive Cancer Center
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|C. Ola Landgren, MD, PhD (Course Chair)||Consultant/Advisor: Amgen Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Global Services, LLC; Karyopharm; Oncopeptides, Inc.; Pfizer Inc.
Speaker’s Bureau: Sanofi Genzyme
|Beth Faiman PhD, MSN, APRN-BC, AOCN, FAAN||Consultant/Advisor: Bristol-Myers Squibb Company; Celgene Corporation; Janssen Global Services, LLC; Karyopharm; Sanofi Genzyme|
|Suzanne Lentzsch, MD, PhD||Consultant/Advisor: Amgen Inc.; Caelum Biosciences;
Celularity Inc.; Clinical Care Options; GlaxoSmithKline; Janssen Global Services, LLC; Oncopeptides, Inc.; Sorrento Therapeutics, Inc.; Takeda Pharmaceutical Company Limited
Grant/Research Support: Karyopharm; Sanofi Genzyme
Stock Option: Caelum Biosciences; Mesoblast Ltd; Poseida Therapeutics
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin; Chelsey Benedek and Emma Boring hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from AbbVie Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AbbVie Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].